Vermont biologics regulations.

Who may administer PRP, exosomes and stem cells in Vermont, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in Vermont?

In Vermont, stem cell and biologic therapies are typically administered by licensed healthcare professionals, such as physicians (MDs/DOs), or physician assistants, and nurse practitioners under supervision. These professionals must hold valid Vermont licenses and meet state certification standards for administering such therapies.

Official sources

Vermont compliance guide.

FDA Compliance

While Vermont does not have biologics-specific regulations beyond federal FDA requirements, the Vermont Department of Health provides valuable resources and standards for healthcare practitioners. Clinics should familiarize themselves with Vermont’s general healthcare practice standards to ensure compliance and alignment with state expectations.

Staying updated with both federal FDA standards and state health guidelines will support comprehensive compliance efforts in Vermont.

Provider Qualifications

In Vermont, stem cell and biologic therapies are typically administered by licensed healthcare professionals, such as physicians (MDs/DOs), or physician assistants, and nurse practitioners under supervision. These professionals must hold valid Vermont licenses and meet state certification standards for administering such therapies.

For current licensing requirements and any recent changes, consult the Vermont Office of Professional Regulation.

Patient Informed Consent

Vermont clinics are required to provide patients with comprehensive informed consent prior to biologic treatments. The consent should cover:

  • A clear explanation of the procedure and its purpose
  • Risks and potential benefits
  • Possible alternatives to the treatment
  • The experimental or investigational nature of biologic therapies, where applicable

Pre-Treatment and Post-Treatment Protocols

Developing standardized pre-treatment and post-treatment protocols helps maintain consistency in care and safety for patients. It is advisable for clinics to implement SOPs for evaluating patient eligibility, administering the treatment, and providing post-treatment care to ensure optimal outcomes and patient satisfaction.

Insurance Requirements

Clinics should verify that their medical liability insurance policy includes coverage for biologic therapies. Confirming this coverage with your provider helps mitigate potential legal and financial risks.

Marketing Compliance

Marketing of biologic therapies must comply with FDA and Vermont advertising standards. Avoid misleading claims, unverified benefits, or unsupported language in promotions. All promotional materials should be accurate, transparent, and include appropriate disclaimers regarding the experimental status of some biologic treatments.

This guide is a general summary to help clinics understand compliance requirements for biologics in Vermont. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

Vermont: common questions.

Who can administer stem cells, PRP and exosomes in Vermont?
In Vermont, stem cell and biologic therapies are typically administered by licensed healthcare professionals, such as physicians (MDs/DOs), or physician assistants, and nurse practitioners under supervision. These professionals must hold valid Vermont licenses and meet state certification standards for administering such therapies. This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in Vermont?
FDA rules are federal, so they apply in Vermont as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in Vermont?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in Vermont?
Start with the live webinar, then a discovery call and live training. After that we verify your Vermont licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in Vermont? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.